The prolonged survival signal in a heavily pretreated population supports UNO's therapeutic potential. Traders should monitor upcoming trial developments and potential partnerships, especially as the company explores combination therapies and earlier-line use.
Price Chart
Executive Summary
Beyond Air's subsidiary Beyond Cancer presented updated Phase 1 trial data at AACR showing prolonged survival in heavily pretreated cancer patients following a single intratumoral UNO injection. The company also received a U.S. patent allowance for its proprietary gas delivery technology, strengthening its IP position.
Key Facts
- Six of ten patients remain alive 22–40 months after a single UNO injection, with median overall survival not yet reached.
- Two triple-negative breast cancer patients show no evidence of disease.
- UNO demonstrated a favorable safety profile with mostly Grade 1–2 adverse events; one non-dose-limiting hypoxia event occurred.
- U.S. Patent and Trademark Office issued a Notice of Allowance for a key delivery system patent.
Financial Impact
Non-dilutive IP and clinical advancement; no direct financial impact reported.
Risk Factors
- Small sample size (n=10) and lack of control arm limit interpretability.
- Early-stage data may not translate into later-stage success.
- Dependence on future financing to advance clinical development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276917 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | SC 13G/A | $2.34 | awaiting T+60 | — | $2.14 (−8.55%) |
Oct 8, 2026 18d ago | 8-K | $2.31 | awaiting T+60 | — | $2.14 (−7.36%) |
Sep 24, 2026 4w ago | 8-K | $2.85 | awaiting T+60 | — | $2.14 (−24.91%) |
Aug 25, 2026 8w ago | EFFECT | $4.98 | awaiting T+60 | — | $2.14 (+57.03%) |
Jul 31, 2026 12w ago | Insider Cluster | $6.33 | awaiting T+60 | — | $2.14 (−66.19%) |
Jul 31, 2026 12w ago | 8-K | $5.28 $2.14 | ▲ +59.43% | ▲ +61.89% | $2.14 (+59.43%) |
Jul 2, 2026 16w ago | Court Ruling | $0.4390 $0.1415 | ▲ +67.77% | ▲ +69.49% | $2.14 (−387.47%) |
Jun 26, 2026 17w ago | 8-K | $0.4646 $0.1505 | ▼ −67.61% | ▼ −71.22% | $2.14 (+360.61%) |
Jun 22, 2026 18w ago | 8-K | $0.4680 $0.1540 | ▼ −67.09% | ▼ −71.05% | $2.14 (+357.26%) |
Apr 20, 2026 27w ago | Press Release | $10.90 $5.55 | ▼ −49.08% | ▼ −55.28% | $2.14 (−80.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers